Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 21.69
(-2.58%)
USD 21.69
(-2.58%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -205.27 Million USD | -16.31% |
| 2022 | -176.49 Million USD | -25.31% |
| 2021 | -140.84 Million USD | -66.58% |
| 2020 | -84.55 Million USD | -224.39% |
| 2019 | 67.97 Million USD | 224.84% |
| 2018 | -54.45 Million USD | -58.38% |
| 2017 | -34.38 Million USD | 57.93% |
| 2016 | -81.72 Million USD | 11.11% |
| 2015 | -91.94 Million USD | -56.81% |
| 2014 | -58.63 Million USD | -88.26% |
| 2013 | -31.14 Million USD | -47.42% |
| 2012 | -21.12 Million USD | -575.19% |
| 2011 | -3.12 Million USD | 45.81% |
| 2010 | -5.77 Million USD | 70.1% |
| 2009 | -19.3 Million USD | 28.72% |
| 2008 | -27.08 Million USD | 9.5% |
| 2007 | -29.93 Million USD | -57.56% |
| 2006 | -18.99 Million USD | -186.76% |
| 2005 | -6.62 Million USD | -165.32% |
| 2004 | -2.49 Million USD | -2521.79% |
| 2003 | -95.23 Thousand USD | 61.32% |
| 2002 | -246.2 Thousand USD | -32.5% |
| 2001 | -185.82 Thousand USD | -35.09% |
| 2000 | -137.55 Thousand USD | -123.2% |
| 1999 | 593 Thousand USD | 1248.79% |
| 1998 | -51.62 Thousand USD | 93.96% |
| 1997 | -854.53 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -170.79 Million USD | -36.31% |
| 2024 Q1 | -132.86 Million USD | -21.14% |
| 2024 Q2 | -125.3 Million USD | 5.69% |
| 2023 Q1 | -41.81 Million USD | 51.35% |
| 2023 Q2 | 48.67 Million USD | 216.42% |
| 2023 Q4 | -109.67 Million USD | -6.54% |
| 2023 FY | -205.27 Million USD | -16.31% |
| 2023 Q3 | -102.94 Million USD | -311.5% |
| 2022 Q4 | -85.94 Million USD | -20.73% |
| 2022 Q2 | 44.36 Million USD | 170.57% |
| 2022 Q1 | -62.87 Million USD | 0.79% |
| 2022 FY | -176.49 Million USD | -25.31% |
| 2022 Q3 | -71.18 Million USD | -260.44% |
| 2021 Q4 | -63.37 Million USD | -111.78% |
| 2021 FY | -140.84 Million USD | -66.58% |
| 2021 Q1 | -20.73 Million USD | 57.19% |
| 2021 Q2 | -26.81 Million USD | -29.36% |
| 2021 Q3 | -29.92 Million USD | -11.58% |
| 2020 Q3 | -13.61 Million USD | 31.38% |
| 2020 Q4 | -48.43 Million USD | -255.83% |
| 2020 Q2 | -19.83 Million USD | -641.87% |
| 2020 FY | -84.55 Million USD | -224.39% |
| 2020 Q1 | -2.67 Million USD | -122.84% |
| 2019 Q1 | 12.03 Million USD | 211.86% |
| 2019 Q3 | 20.33 Million USD | -14.9% |
| 2019 Q4 | 11.7 Million USD | -42.44% |
| 2019 Q2 | 23.89 Million USD | 98.53% |
| 2019 FY | 67.97 Million USD | 224.84% |
| 2018 Q3 | -15.6 Million USD | -4.85% |
| 2018 FY | -54.45 Million USD | -58.38% |
| 2018 Q4 | -10.76 Million USD | 31.04% |
| 2018 Q2 | -14.88 Million USD | -12.77% |
| 2018 Q1 | -13.19 Million USD | -22.99% |
| 2017 Q1 | -12.08 Million USD | 45.61% |
| 2017 FY | -34.38 Million USD | 57.93% |
| 2017 Q2 | -6.04 Million USD | 50.0% |
| 2017 Q4 | -10.73 Million USD | -94.43% |
| 2017 Q3 | -5.51 Million USD | 8.65% |
| 2016 Q3 | -19.42 Million USD | 6.7% |
| 2016 Q2 | -20.81 Million USD | -8.05% |
| 2016 Q4 | -22.22 Million USD | -14.42% |
| 2016 FY | -81.72 Million USD | 11.11% |
| 2016 Q1 | -19.26 Million USD | 22.14% |
| 2015 Q4 | -24.74 Million USD | -55.27% |
| 2015 FY | -91.94 Million USD | -56.81% |
| 2015 Q3 | -15.93 Million USD | 44.44% |
| 2015 Q2 | -28.68 Million USD | -27.06% |
| 2015 Q1 | -22.57 Million USD | -0.65% |
| 2014 Q1 | -10.62 Million USD | 22.38% |
| 2014 Q4 | -22.43 Million USD | -92.89% |
| 2014 Q3 | -11.62 Million USD | 16.59% |
| 2014 Q2 | -13.94 Million USD | -31.18% |
| 2014 FY | -58.63 Million USD | -88.26% |
| 2013 Q1 | -4.61 Million USD | 13.16% |
| 2013 Q2 | -6.75 Million USD | -46.46% |
| 2013 Q3 | -6.07 Million USD | 10.05% |
| 2013 Q4 | -13.69 Million USD | -125.24% |
| 2013 FY | -31.14 Million USD | -47.42% |
| 2012 Q1 | -2.48 Million USD | 10.48% |
| 2012 FY | -21.12 Million USD | -575.19% |
| 2012 Q4 | -5.31 Million USD | 33.51% |
| 2012 Q3 | -7.99 Million USD | -49.79% |
| 2012 Q2 | -5.33 Million USD | -114.65% |
| 2011 FY | -3.12 Million USD | 45.81% |
| 2011 Q1 | -1.43 Million USD | 28.26% |
| 2011 Q2 | 2.9 Million USD | 302.08% |
| 2011 Q3 | -1.81 Million USD | -162.64% |
| 2011 Q4 | -2.77 Million USD | -52.56% |
| 2010 Q3 | -371.05 Thousand USD | 79.99% |
| 2010 Q4 | -2 Million USD | -440.11% |
| 2010 FY | -5.77 Million USD | 70.1% |
| 2010 Q1 | -1.54 Million USD | 55.35% |
| 2010 Q2 | -1.85 Million USD | -20.0% |
| 2009 FY | -19.3 Million USD | 28.72% |
| 2009 Q4 | -3.46 Million USD | -36.83% |
| 2009 Q1 | -8.03 Million USD | 7.25% |
| 2009 Q2 | -5.28 Million USD | 34.13% |
| 2009 Q3 | -2.52 Million USD | 52.19% |
| 2008 Q4 | -8.65 Million USD | -15.41% |
| 2008 Q3 | -7.5 Million USD | -31.74% |
| 2008 Q2 | -5.69 Million USD | -8.81% |
| 2008 Q1 | -5.23 Million USD | 30.89% |
| 2008 FY | -27.08 Million USD | 9.5% |
| 2007 Q2 | -6.17 Million USD | -66.54% |
| 2007 Q1 | -3.7 Million USD | 57.77% |
| 2007 FY | -29.93 Million USD | -57.56% |
| 2007 Q4 | -7.57 Million USD | 39.31% |
| 2007 Q3 | -12.47 Million USD | -102.1% |
| 2006 FY | -18.99 Million USD | -186.76% |
| 2006 Q3 | -3.97 Million USD | -27.93% |
| 2006 Q1 | -3.13 Million USD | -16.41% |
| 2006 Q2 | -3.1 Million USD | 0.97% |
| 2006 Q4 | -8.77 Million USD | -120.92% |
| 2005 Q3 | -3.03 Million USD | -572.39% |
| 2005 Q2 | 642.76 Thousand USD | 141.83% |
| 2005 Q1 | -1.53 Million USD | -4.03% |
| 2005 FY | -6.62 Million USD | -165.32% |
| 2005 Q4 | -2.69 Million USD | 11.25% |
| 2004 Q2 | 30.04 Thousand USD | 114.59% |
| 2004 Q4 | -1.47 Million USD | -131.43% |
| 2004 Q1 | -205.93 Thousand USD | -290.44% |
| 2004 FY | -2.49 Million USD | -2521.79% |
| 2004 Q3 | -638.18 Thousand USD | -2223.83% |
| 2003 Q3 | -53.51 Thousand USD | 48.92% |
| 2003 Q1 | -45.09 Thousand USD | 46.77% |
| 2003 FY | -95.23 Thousand USD | 61.32% |
| 2003 Q4 | 108.13 Thousand USD | 302.08% |
| 2003 Q2 | -104.76 Thousand USD | -132.3% |
| 2002 Q1 | -63.25 Thousand USD | -3.78% |
| 2002 FY | -246.2 Thousand USD | -32.5% |
| 2002 Q4 | -84.72 Thousand USD | 3.82% |
| 2002 Q3 | -88.08 Thousand USD | -767.56% |
| 2002 Q2 | -10.15 Thousand USD | 83.95% |
| 2001 Q4 | -60.94 Thousand USD | -86.68% |
| 2001 FY | -185.82 Thousand USD | -35.09% |
| 2001 Q2 | -51.38 Thousand USD | -25.84% |
| 2001 Q1 | -40.83 Thousand USD | -217.34% |
| 2001 Q3 | -32.64 Thousand USD | 36.47% |
| 2000 Q1 | -60.71 Thousand USD | -21.42% |
| 2000 FY | -137.55 Thousand USD | -123.2% |
| 2000 Q4 | 34.8 Thousand USD | 160.47% |
| 2000 Q2 | -54.09 Thousand USD | 10.9% |
| 2000 Q3 | -57.55 Thousand USD | -6.39% |
| 1999 Q3 | 680 Thousand USD | 3500.0% |
| 1999 FY | 593 Thousand USD | 1248.79% |
| 1999 Q2 | -20 Thousand USD | 0.0% |
| 1999 Q1 | -20 Thousand USD | 0.0% |
| 1999 Q4 | -50 Thousand USD | -107.35% |
| 1998 Q2 | -10 Thousand USD | 0.0% |
| 1998 FY | -51.62 Thousand USD | 93.96% |
| 1998 Q3 | - USD | 100.0% |
| 1998 Q4 | -20 Thousand USD | 0.0% |
| 1997 FY | -854.53 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | -229.733% |
| Codexis, Inc. | -76.24 Million USD | -169.248% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 13.653% |
| Organovo Holdings, Inc. | -14.67 Million USD | -1299.189% |